Sepracor Ends Xopenex Co-Promotion Deal With Abbott; Estorra Reps Will Detail Pulmonary Agent
This article was originally published in The Pink Sheet Daily
Executive Summary
A potential mid-year launch of the insomnia therapy will give Sepracor ample time to prepare for the year-end termination of its Xopenex contract with Abbott's Ross division.